Quantitative EEG in schizophrenia and in response to acute and chronic clozapine treatment (Q43621463)

25 November 2017

title

Quantitative EEG in schizophrenia and in response to acute and chronic clozapine treatment (English)

1 reference

25 November 2017

0 references

V Knott

1

1 reference

25 November 2017

A Labelle

series ordinal

2

1 reference

25 November 2017

B Jones

series ordinal

3

1 reference

25 November 2017

C Mahoney

series ordinal

4

1 reference

25 November 2017

language of work or name

English

0 references

publication date

1 May 2001

1 reference

25 November 2017

published in

Schizophrenia Research

1 reference

25 November 2017

volume

50

1 reference

25 November 2017

issue

1-2

1 reference

25 November 2017

page(s)

41-53

1 reference

Quantitative EEG in schizophrenic patients before and during pharmacotherapy

25 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900165-1

7 January 2021

The comparative efficacy and long-term effect of clozapine treatment on neuropsychological test performance.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900165-1

7 January 2021

Pretreatment EEG predicts short-term response to haloperidol treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900165-1

7 January 2021

Level of haloperidol in plasma is related to electroencephalographic findings in patients who improve

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900165-1

7 January 2021

Theoretical and practical importance of plasma levels of haloperidol. correlations with clinical and computerized EEG data

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900165-1

7 January 2021

Physical aspects of the EEG in schizophrenics

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900165-1

7 January 2021

Intra and inter-hemispheric changes in alpha intensities in EEGs of schizophrenic patients versus matched controls

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900165-1

7 January 2021

EEG activation patterns during the performance of tasks involving different components of mental calculation.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900165-1

7 January 2021

EEG Profile Studies of Clozapine in Volunteers and Psychiatric Patients

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900165-1

7 January 2021

Clozapine. A review of its pharmacological properties, and therapeutic use in schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900165-1

7 January 2021

Spontaneous motor activity in healthy volunteers after single doses of haloperidol

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900165-1

7 January 2021

Pharmacologic strategies for augmenting cognitive performance in schizophrenia.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900165-1

7 January 2021

Topographical distribution of absolute alpha-power in the EEG and psychopathology in schizophrenic outpatients

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900165-1

7 January 2021

C-EEG brain mapping in DSM-III schizophrenics after acute and chronic haloperidol treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900165-1

7 January 2021

CEEG mapping in drug-free schizophrenics. Differences from healthy subjects and changes induced by haloperidol treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900165-1

7 January 2021

QEEG alpha 1 changes after a single dose of high-potency neuroleptics as a predictor of short-term response to treatment in schizophrenic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900165-1

7 January 2021

Multilead quantitative EEG profile of clozapine in resting and vigilance-controlled conditions

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900165-1

7 January 2021

Schizophrenia and EEG spectral analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900165-1

7 January 2021

The effect of clozapine on cognition and psychiatric symptoms in patients with schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900165-1

7 January 2021

EEG mapping of left hemisphere dysfunction during motor performance in schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900165-1

7 January 2021

Bilateral brain dysfunction during motor activation in type II schizophrenia measured by EEG mapping

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900165-1

7 January 2021

EEG alterations and seizures during treatment with clozapine. A retrospective study of 283 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900165-1

7 January 2021

Improvement in cognitive functions and psychiatric symptoms in treatment-refractory schizophrenic patients receiving clozapine.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900165-1

7 January 2021

EEG alterations in patients treated with clozapine in relation to plasma levels

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900165-1

7 January 2021

Development of a classification rule for four clinical therapeutic psychotropic drug classes with EEG power-spectrum variables of human volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900165-1

7 January 2021

The effects of clozapine on symptom reduction, neurocognitive function, and clinical management in treatment-refractory state hospital schizophrenic inpatients.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900165-1

7 January 2021

Qualitative and Quantitative EEG Findings in Schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900165-1

7 January 2021

Quantitative EEG Brain Mapping In Psychotropic Drug Development, Drug Treatment Selection, and Monitoring

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900165-1

7 January 2021

HZI systems for EEG parametrization and classification of psychotropic drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900165-1

7 January 2021

Computerized EEG as a Predictor of Drug Response in Treatment Resistant Schizophrenics

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900165-1

7 January 2021

Letter: The epsilon-adjustment procedure for repeated-measures analyses of variance

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900165-1

7 January 2021

Clozapine increases EEG photic driving in clinical responders

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900165-1

7 January 2021

Topographic analysis of EEG photic driving in patients with schizophrenia following clozapine treatment.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900165-1

7 January 2021

Quantitative electrophysiological characteristics and subtyping of schizophrenia.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900165-1

7 January 2021

Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900165-1

7 January 2021

Computed electroencephalographic activity mapping in schizophrenia. The resting state reconsidered

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900165-1

7 January 2021

Alpha frequency in schizophrenia: an association with enlarged cerebral ventricles

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900165-1

7 January 2021

Reliability and validity of the positive and negative syndrome scale for schizophrenics

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900165-1

7 January 2021

Computerized EEG topography findings in schizophrenic patients before and after haloperidol treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900165-1

7 January 2021

The effect of acute tryptophan depletion and fenfluramine on quantitative EEG and mood in healthy male subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900165-1

7 January 2021

Paroxysmal EEG Activity and Psychopathology During the Treatment with Clozapine

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900165-1

7 January 2021

A psychobiological model of the pathogenesis of schizophrenic symptoms

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900165-1

7 January 2021

Drug-Induced Paroxysmal EEG-Activities

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900165-1

7 January 2021

Effects of granisetron and haloperidol, alone and in combination, on psychometric performance and the EEG

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900165-1

7 January 2021

Saccadic eye movements in tracking, fixation, and rest in schizophrenic and normal subjects.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900165-1

7 January 2021

A comparison of the central nervous system effects of haloperidol, chlorpromazine and sulpiride in normal volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900165-1

7 January 2021

Negative symptoms and EEG alpha activity in schizophrenic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900165-1

7 January 2021

EEG asymmetry in schizophrenic patients before and during neuroleptic treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900165-1

7 January 2021

EEG coherence in unmedicated schizophrenic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900165-1

7 January 2021

Localization of sources of brain alpha/theta/delta activity and the influence of the mode of spontaneous mentation.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900165-1

7 January 2021

Computerized EEG in schizophrenic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900165-1

7 January 2021

Structure and function: brain electrical activity mapping and computed tomography in schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900165-1

7 January 2021

Brain electrical activity mapping (BEAM) in schizophrenic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900165-1

7 January 2021

Altered topography of EEG spectral content in schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900165-1

7 January 2021

Computed EEG in schizophrenics

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900165-1

7 January 2021

EEG coherence in unmedicated schizophrenic patients: topographical study of predominantly never medicated cases

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900165-1

7 January 2021

QEEG profiles of psychiatric disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900165-1

7 January 2021

Cognitive improvement in schizophrenia with novel antipsychotic medications

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900165-1

7 January 2021

Quantitative EEG, SPEM, and psychometric studies in schizophrenics before and during differential neuroleptic therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900165-1

7 January 2021

Comparative placebo-controlled pharmacodynamic studies with zotepine and clozapine utilizing pharmaco-EEG and psychometry.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900165-1

7 January 2021

EEG-brain mapping in schizophrenics with predominantly positive and negative symptoms. Comparative studies with remoxipride/haloperidol

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900165-1

7 January 2021

EEG-brain mapping. A method to optimize therapy in schizophrenics using absolute power and center frequency values

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900165-1

7 January 2021

Quantitative EEG and BPRS data following Haldol-Decanoate administration in schizophrenics

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900165-1

7 January 2021

A comparison of the effects of clozapine and olanzapine on the EEG in patients with schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900165-1

7 January 2021

Eye blink and schizophrenia: psychosis or tardive dyskinesia?

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900165-1

7 January 2021

Ritanserin, a 5-HT2 receptor antagonist, activates midbrain dopamine neurons by blocking serotonergic inhibition

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900165-1

7 January 2021

Background EEG reactivity in auditory event-related potentials

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900165-1

7 January 2021

Clozapine-induced seizures and EEG changes

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900165-1

7 January 2021

Slower theta activity over the midfrontal cortex in schizophrenic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900165-1

7 January 2021

The effects of haloperidol on the EEG spectrum

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900165-1

7 January 2021

Frontal spectral EEG findings in acutely ill schizophrenics

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900165-1

7 January 2021

10.1016/S0920-9964(00)00165-1

Identifiers

DOI

1 reference

25 November 2017

1 reference